Research Summary

Dr. Hala Borno is faculty at UCSF and an Assistant Professor in the Department of Medicine and Division of Hematology/Oncology and co-Medical Director of the Genitourinary Medical Oncology Clinic at the Helen Diller Family Comprehensive Cancer Center (HDFCCC) at the University of California San Francisco (UCSF). Dr. Borno is a medical oncologist with clinical expertise in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. At HDFCCC, Dr. Borno serves on the executive leadership committee for the Prostate Cancer Program and the Liaison to the Office of Community Engagement. She is also a member of the American Society of Clinical Oncology Social Determinants of Health working group, and GU committee for NRG oncology. She serves as the Vice Chair of the Health Disparities Committee for Alliance for Clinical Trials in Oncology.

Dr. Borno's research program consists of prostate cancer therapeutic development and cancer disparities. She serves as medical oncology co-chair for phase III clinical trials and is the principal investigator for clinical trials conducted at HDFCCC in advanced prostate cancer. Dr. Borno has an extensive research program on the promotion of equity in cancer precision medicine.

She has developed novel recruitment technologies that are clinician and patient facing to promote diversity and inclusion of racial/ethnic minorities in clinical trials. Dr. Borno used human-centered design to develop Trial LibraryTM, a patient facing clinical trial matching tool. Dr. Borno's research has been featured in peer-reviewed journals such JAMA Oncology, Cancer, and Nature. Her work has been covered by national news outlets such as NPR, Washington Post, CBS News, Bloomberg News, and STAT News.

Dr. Borno graduated with honors in biochemistry and received her medical degree from the University of North Carolina at Chapel Hill where she was a Medical Alumni Loyalty Fund Scholar. She completed her internal medicine residency and medical oncology fellowship training at UCSF. She served as chief oncology fellow at UCSF and was a National Institute on Aging T32 research fellow in the Division of Geriatrics.


University of North Carolina at Chapel Hill, B.S., 05/2008, Biochemistry
University of North Carolina at Chapel Hill, M.D., 05/2013, Medicine
University of California, San Francisco, Intern, 06/2014, Internal Medicine
University of California, San Francisco, Resident, 06/2016, Internal Medicine

Honors & Awards

  • 2009
    Foreign Language Area Studies Fellowship
  • 2011-2012
    Furlow Fund Global Health Research Fellowship, University of North Carolina at Chapel Hill
  • 2009-2013
    Medical Alumni Loyalty Fund Scholarship
  • 2013
    Arnold P. Gold Foundation
  • 2013
    Daniel T. Young Peace and Social Justice Award
  • 2017-present
    Geriatrics T32 NIH Grant
  • 2017-present
    Inside Out Accelerator Grant from the Clinical Innovation Center

Selected Publications

  1. Hala T. Borno, Tracy Kuo Lin, Sylvia Zhang, Andrea Skafel, Alyssa Lalanne, Dana Dornsife, Robert Johnson, Darcy Spicer, Eric J. Small, Kim F. Rhoads. Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. Journal of Cancer Policy. 2021 Dec 1; 30:100305.  View on PubMed
  2. Palmer NR, Borno HT, Gregorich SE, Livaudais-Toman J, Kaplan CP. Prostate cancer patients' self-reported participation in research: an examination of racial/ethnic disparities. Cancer Causes Control. 2021 Oct; 32(10):1161-1172.  View on PubMed
  3. Mary Kathryn Abel, Michelle E. Melisko, Hope S. Rugo, Amy Jo Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura Esserman, Hala Borno, Rita A. Mukhtar. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):1092-1092.  View on PubMed
  4. Rahul Raj Aggarwal, Srey Luch Sam, Vadim S Koshkin, Eric Jay Small, Felix Y Feng, Ivan de Kouchkovsky, Daniel H Kwon, Terence W. Friedlander, Hala Borno, Rohit Bose, Jonathan Chou, Arpita Desai, Tammy J. Rodvelt, Maya Aslam, Medini Rastogi, Lawrence Fong, Thomas A Hope. Immunogenic priming with 177 Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):5053-5053.  View on PubMed
  5. Michael Glover, Julie Wu, Daniel H Kwon, Sylvia Zhang, Solomon Henry, Douglas Wood, Daniel Rubin, Hala Borno, Eric Jay Small, Lidia Schapira, Vadim S Koshkin, Sumit Shah. Patterns in cancer management changes for patients with COVID-19 in northern California. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):1535-1535.  View on PubMed
  6. Daniel H Kwon, Alan Paciorek, Li Zhang, Hala Borno, Arpita Desai, Rohit Bose, Jonathan Chou, Lawrence Fong, Terence W. Friedlander, Franklin W. Huang, Vadim S Koshkin, Eric Jay Small, Rahul Raj Aggarwal. Rate of skeletal-related events (SREs) for abiraterone acetate (AA) versus enzalutamide (ENZ) in prostate cancer: A population-based study using the SEER-Medicare database. Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e17038-e17038.  View on PubMed
  7. Divya V Natesan, Li Zhang, David Yoonsuk Oh, Sima P. Porten, Maxwell Meng, Raj Pruthi, Matthew R. Cooperberg, Peter Carroll, Jonathan Chou, Hala Borno, Rohit Bose, Arpita Desai, Daniel H Kwon, Anthony C. Wong, Felix Y Feng, Rahul Raj Aggarwal, Eric Jay Small, Lawrence Fong, Terence W. Friedlander, Vadim S Koshkin. Updated results of phase II trial using escalating doses of neoadjuvant atezolizumab for cisplatin-ineligible patients with nonmetastatic urothelial cancer (NCT02451423). Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):e16510-e16510.  View on PubMed
  8. Borno HT, Andemeskel G, Palmer NR. Redefining Attribution From Patient to Health System-How the Notion of "Mistrust" Places Blame on Black Patients. JAMA Oncol. 2021 May 01; 7(5):780.  View on PubMed
  9. Miaskowski C, Paul SM, Snowberg K, Abbott M, Borno HT, Chang SM, Chen LM, Cohen B, Cooper BA, Hammer MJ, Kenfield SA, Kober KM, Laffan A, Levine JD, Pozzar R, Rhoads K, Tsai KK, Van Blarigan EL, Van Loon K. Loneliness and symptom burden in oncology patients during the COVID-19 pandemic. Cancer. 2021 09 01; 127(17):3246-3253.  View on PubMed
  10. Kelsey H Natsuhara, Li Zhang, Christopher A Carlos, Hala T Borno. Evaluating predictors of renal injury with sorafenib in hepatocellular carcinoma: A multi-ethnic cohort study. Journal of Onco-Nephrology. 2021 Apr 19; 239936932110092.  View on PubMed
  11. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 Jun 15; 127(12):1965-1973.  View on PubMed
  12. Rabow M, Wang C, Zhang S, Tahir PM, Small EJ, Borno HT. Examining reporting and representation of patients with cancer in COVID-19 clinical trials. Cancer Rep (Hoboken). 2021 08; 4(4):e1355.  View on PubMed
  13. Daniel Kwon, Rohit Vashisht, Hala Borno, Rahul Raj Aggarwal, Eric Jay Small, Atul Butte, Franklin W. Huang. Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):37-37.  View on PubMed
  14. Hala Borno, Sylvia Zhang, Scarlett Lin Gomez, Celia Kaplan, Christine Miaskowski, Julian Hong, Dame Idossa, Adina Bailey, Eric Jay Small. Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):38-38.  View on PubMed
  15. Ronald C. Chen, Theodore Karrison, Colleen Anne Lawton, William Adrian Hall, Hala Borno, Mihaela Rosu, Ashesh B. Jani, David M. Schuster, Michael J. Seider, Jason A. Efstathiou, Edwin Melencio Posadas, Paul L. Nguyen, Felix Y Feng. INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):tps179-tps179.  View on PubMed
  16. Hala Borno, Patricia Li, Sylvia Zhang, Dame Idossa, Arpita Desai, Tammy J. Rodvelt, Rohit Bose, Vadim S Koshkin, Jonathon Chou, Terence W. Friedlander, Franklin W. Huang, Eric Jay Small, Rahul Raj Aggarwal. Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):19-19.  View on PubMed
  17. Barry Tong, Hala Borno, Fern Alagala, Kelly Gordon, Eric Jay Small, Amy M. Lin, Amie Blanco, Mallika Sachdev Dhawan. Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Journal of Clinical Oncology. 2021 Feb 20; 39(6_suppl):66-66.  View on PubMed
  18. Errol J. Philip, Sylvia Zhang, Peggy Tahir, Daniel Kim, Francis Wright, Alexander Bell, Hala T. Borno. Cost-Effectiveness of Immunotherapy Treatments for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer. 2021 Feb 12; 1-16.  View on PubMed
  19. Kwon DH, Vashisht R, Borno HT, Aggarwal RR, Small EJ, Butte AJ, Huang FW. Androgen-deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry. Ann Oncol. 2021 05; 32(5):678-679.  View on PubMed
  20. Errol J. Philip, Nichole Legaspi, Hala T. Borno. Integrating Financial Toxicity Assessment in Cancer Treatment: Implications for Medical Oncology Training. Journal of Health Science Research. 2021 Jan 29; 30-38.  View on PubMed

Go to UCSF Profiles, powered by CTSI